We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Preventing Cognitive Decline by Reducing BP Target Trial (PCOT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05106036
Recruitment Status : Recruiting
First Posted : November 3, 2021
Last Update Posted : September 1, 2022
Sponsor:
Collaborators:
National Institute on Aging (NIA)
Duke University
Parkland Health and Hospital System
Information provided by (Responsible Party):
Miguel Vazquez, University of Texas Southwestern Medical Center

Brief Summary:
The PCOT study is a multi-site randomized trial of patients 70 years or older with high BP. The main goal of the study Preventing Cognitive Decline by Reducing BP Target Trial (PCOT) is to conduct a large pragmatic clinical trial (PCT) to test the hypothesis that patients who receive care with a combination of clinical decision support (CDS) and team-based care delivered in primary care practices will have better blood pressure control and a lower incidence of mild cognitive impairment and dementia than patients receiving usual medical care. Patients will be recruited from UT Southwestern Medical Center and Parkland Health & Hospital System.

Condition or disease Intervention/treatment Phase
Cognitive Decline Blood Pressure Hypertension Other: Clinical Support Decision Tool Not Applicable

Detailed Description:

Aim 1 The main aim is to compare the effects of intensive BP intervention between the intervention and usual care arm on the rate of change in TICS-m per year. The investigators will recruit 4,000 patients over 70 years of age with BP >130/80 mmHg from 2 diverse health systems and randomize patients within each health system to usual care or to a combination of care with clinical decision support, practice facilitators and Pharm Ds to lower home BP to < 130/80 mmHg. The primary outcome of this trial will be development cognitive decline as determined by a decrease in TICS-m scores from baseline. As a secondary outcome, the investigators will also measure the development of mild cognitive impairment or dementia in a subset of patients who show a decline of ≥3 points through adjudication.

Aim 2a Determine the potential harms of intensive lowering BP. The investigators aim to recruit 4,000 study participants and compare the effects of lowering home BP below 130/80 mmHg with usual care on hospitalizations, emergency department visits, cardiovascular events, deaths, syncope, falls, fractures, hypotension, electrolyte abnormalities and acute kidney injury. The investigators will capture measures of adherence and health care resource utilization. The investigators will assess QOL in 4,000 patients. The investigators will capture possible harms of lowering BP below 130/80 mmHg. The investigators have chosen clinical outcomes of relevance to all the stakeholders based on prior experience on pragmatic clinical trials and our prior experience in ICD-Pieces. Outcomes will be captured from the telephone assessment by study personnel and electronic health records and/or claims data and reflecting possible harms from all participants will include hospitalizations, emergency department visits, cardiovascular events, deaths, syncope, hypotension, falls, fractures, electrolyte disturbances and acute kidney injury. There will also be capture of adherence by pharmacy refill data. The investigators will capture BP readings from each visit. The investigators will also capture number of encounters with the health system as a measure of health care utilization.

Aim 2b Determine the impact of intensive BP management on QOL. Determine the impact of intensive BP management on QOL. Quality of life (QOL) scores will be obtained using the PROMIS Scale v1.2 - Global Health instrument annually after the administration of the TICS-m.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 4000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Preventing Cognitive Decline by Reducing BP Target Trial
Actual Study Start Date : July 11, 2022
Estimated Primary Completion Date : August 31, 2025
Estimated Study Completion Date : August 31, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention Arm
Home BP data will be averaged each month via OmronConnect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health.Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the CDS (Clinical Decision Support) tool to assist their physicians with their blood pressure management. Study Team will not be involved in treatment decision making, it will be determined by subject's treating physician. .
Other: Clinical Support Decision Tool
Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.

No Intervention: Usual Care Arm
Physicians will continue to make decisions about the participant's blood hypertension management as usual without the CDS tool.



Primary Outcome Measures :
  1. Cognitive Decline [ Time Frame: 4 years ]
    Rate of change in Modified Telephone Interview for Cognitive Status (TICS-m) test between study arms. The test has scores ranging from 0 to 42 with higher values indicating better cognitive status.


Secondary Outcome Measures :
  1. Mild Cognitive Decline or Dementia [ Time Frame: 4 years ]
    Development of mild cognitive decline or dementia as determined through adjudication from cognitive experts between study arms


Other Outcome Measures:
  1. Number of Pharmacy Refills [ Time Frame: 4 years ]
    Between the two groups

  2. Change in quality of life assessment [ Time Frame: 4 years ]
    Quality of life (QOL) scores will be obtained using the PROMIS Scale v1.2 - Global Health instrument annually. The investigators will assess change in quality of life across the four years between the two groups. The Global Health instrument has scores ranging from 4 to 20 for their Mental and Physical Health Items with higher values indiciating better global health.

  3. Number of encounters within the participant's health system [ Time Frame: 4 years ]
    The number of encounters within the participant's respective health system between the two groups will be used to assess healthcare utilization.

  4. Systolic and Diastolic BP Readings [ Time Frame: 4 years ]
    Between the two groups

  5. Combination Pill Use [ Time Frame: 4 years ]
    Between the two groups

  6. BP Above 130/80 [ Time Frame: 4 years ]
    Between the two groups

  7. Count of individuals who experience any of the following safety events: hospitalizations and emergency room visits [ Time Frame: 4 years ]
    Total number of hospitalizations and emergency room visits related to cardiovascular events, syncope, hypotension, falls, fractures, electrolyte disturbances and acute kidney injury between the two groups.

  8. Number of reported deaths [ Time Frame: 4 years ]
    Count of the number of reported deaths between the two groups



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • High BP defined as at least 2 BP readings of SBP >= 130 or DBP >=80 during the 24 months prior to enrollment
  • Clinic visit with primary care provider within the last 24 months
  • Ability to write and speak English or Spanish
  • 70 years of age or older 5 - Ability to understand and willingness to provide informed consent
  • Owns a smartphone or tablet

Exclusion Criteria:

  • Blood pressure consistently <130/80 mmHg
  • Presence of dementia, Alzheimer's disease, or significant neurological disease
  • Major and unstable heart disease (e.g., acute heart failure (systolic or diastolic), acute on chronic heart failure (systolic or diastolic), acute coronary syndrome or cardiac arrest, liver or renal transplantation
  • Under 70 years of age
  • Inability to write or speak English or Spanish
  • Chronic kidney disease stage 5 or ESKD
  • Chemotherapy
  • Any conditions judged by the medical providers to contraindicate participation due to risk to patient safety or lack of adherence
  • Expected life expectancy under a year

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05106036


Contacts
Layout table for location contacts
Contact: Venkatraghavan Sundaram, Ph.D. 214-590-3848 venkatraghavan.sundaram@phhs.org
Contact: Miguel Vazquez, MD 214-648-3442 miguel.vazquez@utsoutwestern.edu

Locations
Layout table for location information
United States, Texas
UT Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Miguel Vazquez, MD    214-648-3442    Miguel.Vazquez@UTSouthwestern.edu   
Contact: Wanpen Vongpatanasin, MD    214-648-9078    Wanpen.Vongpatanasin@UTSouthwestern.edu   
Sponsors and Collaborators
University of Texas Southwestern Medical Center
National Institute on Aging (NIA)
Duke University
Parkland Health and Hospital System
Layout table for additonal information
Responsible Party: Miguel Vazquez, Professor, Clinical Director, Division of Nephrology, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT05106036    
Other Study ID Numbers: STU 2021-0735
R33AG068486 ( U.S. NIH Grant/Contract )
First Posted: November 3, 2021    Key Record Dates
Last Update Posted: September 1, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders